Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd is a Shanghai-based developer of cell-based therapy technologies for cancer treatment.

JW Therapeutics is a cellular immunotherapy company that has an integrated platform which focuses on the development, manufacturing and commercialization of breakthrough cell-based immunotherapies for hematological cancers and solid tumors.

The vision of JW Therapeutics vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. The company has built a comprehensive and differentiated cell therapy pipeline that covers both hematological cancers and solid tumors. Its lead product, relmacabtagene autoleucel, is an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma, it is expected to become the first CAR-T therapy to gain an approval as a Category 1 biologics product in China.

JW Therapeutics has the vision to become an Innovation Leader in Cell Immunotherapy and its mission is to bring hope to patients in China, work together, and realize its potential and that of Its employees.


March 8, 2018
JW (Cayman) Therapeutics Co. Ltd raises a $90,000,000 series A round.
JW (Cayman) Therapeutics Co. Ltd was founded by James Li.

Funding rounds


Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.